Disease Flare with Gonadotrophin-Releasing Hormone (GnRH) Analogues

@article{Scaletscky1993DiseaseFW,
  title={Disease Flare with Gonadotrophin-Releasing Hormone (GnRH) Analogues},
  author={R Scaletscky and J Smith},
  journal={Drug Safety},
  year={1993},
  volume={8},
  pages={265-270}
}
View on Springer
ncbi.nlm.nih.gov
5 Citations
Background Citations
2

5 Citations

Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer
TLDR
Overall, collected data suggest that the LA gel depot can represent the ADT reference therapy in advanced PCa, and results of the registration studies and post-marketing clinical trials demonstrate that theLA gel depot provides long-term efficacy in the clinical practice and a good degree of tolerability.
Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
TLDR
Two weeks of priming with CPA does not eliminate the surge in serum testosterone (testosterone flare) upon LHRHA administration but the testosterone increase does not exceed pretreatment levels and 2 weeks of CPA may not offer a benefit over 1 week in lowering serum testosterone.
A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer
TLDR
The literature supporting early, adjuvant LHRH therapy and Eligard® 7.5 mg, a new depot formulation of leuprolide acetate that uses the Atrigel® drug delivery system, causing an increase in bioavailability and optimising testosterone suppression are focused on.
A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
TLDR
Clinical trials in men with advanced prostatic cancer demonstrate that leuprorelin (usually monthly depot injections of 3.75 or 7.5 mg) is less likely to cause serious adverse cardiovascular effects than diethylstilbestrol, and has comparable efficacy to bilateral orchiectomy or other GnRH analogues.

References

SHOWING 1-10 OF 22 REFERENCES
Inhibition of LHRH-Analogue Induced Testosterone Surge by Blockade of Androgen Receptors
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
TLDR
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.
A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate
From April 1983 to March 1985, 265 patients with newly diagnosed metastatic prostate cancer were randomized to one of three treatment protocols: (1) diethylstilbestrol (DES) or bilateral Orchiectomy,…
Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
TLDR
In patients with histologically confirmed prostate cancer, oestrogen priming with diethylstilboestrol for 4 weeks prior to the first injection of the LHRH agonist Zoladex prevented any rise in the serum testosterone concentration.
Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
Luteinizing hormone-releasing hormone (LHRH) agonists for treatment of advanced prostatic carcinoma.
Priapism in hypogonadal men receiving gonadotropin releasing hormone.
Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone.
  • T. Redding, D. Coy, A. Schally
  • Medicine, Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1982
TLDR
The inhibitory effects of these antagonistic analogues on rat prostate tumors suggest that these compound might be considered in the development of new types of therapy for prostate carcinoma and other endocrine-dependent neoplasias.
Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
TLDR
It is concluded that nilutamide can prevent the adverse consequences of the buserelin-induced transient rise in plasma testosterone levels in men with advanced prostate cancer treated with a GnRH analogue.
Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
TLDR
A multicentre, randomised trial in the United Kingdom and the Republic of Ireland, in which the LHRH analogue Zoladex, administered subcutaneously every 28 days, was compared with orchiectomy found both treatments were equally effective in lowering serum testosterone concentrations to within the surgically castrate range.
...
...